Timing of Recurrence After Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer
Descripción general
Resumen del artículo
In a review of five clinical trials, most recurrences of triple-negative breast cancer after neoadjuvant chemo-immunotherapy occurred within 24 months. This pattern was even more pronounced in patients with residual disease after initial treatment, emphasizing the need for improved strategies to prevent early relapse. The study was limited by its reliance on extracted data from published survival curves and heterogeneity across the included trials.
Explícamelo como si tuviera cinco años
Most patients with triple-negative breast cancer who experience recurrence after chemo-immunotherapy do so within two years of starting treatment, highlighting a need for better strategies to prevent early relapse.
Posibles conflictos de intereses
Multiple authors disclosed financial ties to pharmaceutical companies involved in cancer treatment, including consulting fees, honoraria, research funding, and advisory board positions.
Limitaciones identificadas
Explicación de la calificación
This study provides valuable insights into the timing of recurrence in a high-risk patient population. The analysis of multiple clinical trials strengthens the findings, but the limitations related to data source and heterogeneity across trials warrant a slightly lower rating than a 5.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →